{"entity":{"id":"nct05332561","kind":"trial","name":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","aka":[],"tldr":"This German study assigns additional treatment after surgery according to tumour profiling. Its olaparib arm can accept qualifying tumour-only BRCA alterations.","summary":"The registry lists NCT05332561 as recruiting, last updated 2025-03-20. Enrolment is 240 planned participants, an estimate. Interventions: Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib, Olaparib, Sacituzumab govitecan, Trastuzumab/pertuzumab. Primary measures include Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery. No results are posted in the registry; this does not exclude separate publications. The current registry lists German sites and no US site. Arm 4 accepts inactivating somatic or germline BRCA1/2, including homozygous deletions, or inactivating germline PALB2, with assignment exclusively determined by the molecular tumour board. Separate arms target separate pathways; the platform is not a combined PARP regimen or proof of adjuvant benefit for somatic-only BRCA.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT05332561","url":"https://clinicaltrials.gov/study/NCT05332561"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05332561","phase":"2","setting":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE","sponsor":"German Cancer Research Center","participation":[{"nct":"NCT05332561","source":"https://clinicaltrials.gov/study/NCT05332561","fetchedAt":"2026-10-07T16:53:40.482Z","studySha256":"c5b52baa192d440c0c15ed52cd903cd08e9b28b7742423fa327f29d05a0aea1e","overallStatus":"RECRUITING","lastUpdatePosted":"2025-03-20","leadSponsor":"German Cancer Research Center","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":240,"enrolmentType":"ESTIMATED","siteCount":9,"recruitingSiteCount":7,"countries":["Germany"]}],"started":"2023-06-29","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05332561/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}]}}